Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN

Award Number: R41CA261451
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/08/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN - Project Summary The goal of this project is to establish an effective drug candidate to treat chemotherapy-induced peripheral neuropathy (CIPN). The National Cancer Institute estimates that approximately 400,000 (or ~60-70%) of patients undergoing chemotherapy suffer from CIPN. These patients may need to terminate chemotherapy treatment if experiencing symptoms, such as numbness, pain, temperature sensitivity, or tingling. Cancer survivors furthermore often have to live with CIPN for the rest of their lives. To date are no treatments available with which to tackle this problem. CIPN costs the healthcare system upward of $13B annually for long-term care of the patients. Thus, there is a significant clinical and economical need to develop drug therapies. Avantyx Pharmaceuticals, LLC has identified a new compound targeting the Matrix-Metalloproteinase 13 (MMP-13), which was shown to promote the degeneration of sensory nerve endings in animal models for CIPN induced by paclitaxel treatment. The key focus of this Phase I project is to characterize a novel MMP-13 inhibitor for its bioavailability, efficacy, specificity, and toxicity in a rat model of paclitaxel-induced peripheral neuropathy, which is following studies in which we established the efficacy of this inhibitor in zebrafish. Key goals are to establish parameters, such as optimal route of administration (oral or topical), optimal dosing, and target specificity, which is necessary to proceed to further drug development studies in Phase II.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	AVANTYX, LLC	1951 NW 7TH AVENUE	MIAMI	FL	33136	MIAMI-DADE	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	2/13/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $355,723 )
2021	2021	AVANTYX PHARMACEUTICALS, LLC	7901 SW 176TH ST	MIAMI	FL	33157	MIAMI-DADE	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	1	9/9/2021	NEW	$5,059
2021	2021	AVANTYX PHARMACEUTICALS, LLC	7901 SW 176TH ST	MIAMI	FL	33157	MIAMI-DADE	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/8/2021	NEW	$350,664
														Subtotal = $355,723

Grand Total All Awards = $355,723

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN

Award Number: R41CA261451

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/08/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer